Skip to main content
Top
Published in: Calcified Tissue International 5/2014

01-11-2014 | Original Research

Identifying Atypical Femoral Fractures—A Retrospective Review

Authors: Angela G. Juby, Sean Crowther, Marilyn Cree

Published in: Calcified Tissue International | Issue 5/2014

Login to get access

Abstract

Subtrochanteric atypical femoral fractures (AFFs) have been reported in patients on osteoporosis therapy (bisphosphonates and denosumab). In 2010, and again in 2013, the ASBMR AFF Task Force developed strict diagnostic criteria for AFFs. This is the first study using these criteria to define the prevalence of AFFs in Canada. This study is a retrospective review of all adult patients (April 2002–March 2013) with an ICD 10 code for hip, femoral or subtrochanteric fracture, from two referral hospitals in Alberta, Canada. All identified as isolated subtrochanteric fractures were further evaluated by chart review, prescription review and examination of radiographs. Of 349 subjects, 79 had isolated subtrochanteric fractures. Of the 70 cases of subtrochanteric fractures that were radiographically assessed (9 films unavailable), 41 fulfilled ASBMR 2013 AFF criteria. The remaining subjects had subtrochanteric fractures but did not meet the ASBMR criteria to qualify as AFFs. There were 11 AFFs in 2012/2013, giving a rate of AFFs of 1.42 per 100,000 50 + year adults, compared to a rate of 103.47 per 100,000 50+ year adults for typical hip fractures. Isolated subtrochanteric fractures are rare. They cannot reliably be identified by ICD coding alone. In this study, only 59 % of all isolated subtrochanteric/femoral shaft fractures fulfilled the ASBMR task force criteria for true AFFs. The rate of typical hip fractures was substantially higher than the rate of AFFs, defined by ASBMR diagnostic criteria.
Literature
1.
go back to reference Abrahamsen B, Eiken P, Eastell R (2010) Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis. J Clin Endocrinol Metab 95:5258–5265PubMedCrossRefPubMedCentral Abrahamsen B, Eiken P, Eastell R (2010) Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis. J Clin Endocrinol Metab 95:5258–5265PubMedCrossRefPubMedCentral
2.
go back to reference Hsiao FY, Huang WF, Chen YM et al (2011) Hip and subtrochanteric or diaphyseal femoral fractures in alendronate users: a 10-year, nationwide retrospective cohort study in Taiwanese women. Clin Ther 33:1659–1667PubMedCrossRef Hsiao FY, Huang WF, Chen YM et al (2011) Hip and subtrochanteric or diaphyseal femoral fractures in alendronate users: a 10-year, nationwide retrospective cohort study in Taiwanese women. Clin Ther 33:1659–1667PubMedCrossRef
3.
go back to reference Lenart BA, Lorich DG, Lane JM (2008) Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 358:1304–1306PubMedCrossRef Lenart BA, Lorich DG, Lane JM (2008) Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 358:1304–1306PubMedCrossRef
4.
go back to reference Salminen ST, Pihlajamäki HK, Avikainen VJ, Böstman OM (2000) Population based epidemiologic and morphologic study of femoral shaft fractures. Clin Orthop Relat Res 372:241–249PubMedCrossRef Salminen ST, Pihlajamäki HK, Avikainen VJ, Böstman OM (2000) Population based epidemiologic and morphologic study of femoral shaft fractures. Clin Orthop Relat Res 372:241–249PubMedCrossRef
5.
go back to reference Lenart BA, Neviaser AS, Lyman S et al (2009) Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int 20:1353–1362PubMedCrossRef Lenart BA, Neviaser AS, Lyman S et al (2009) Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int 20:1353–1362PubMedCrossRef
6.
go back to reference Shane E, Burr D, Ebeling PR et al (2010) Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 25:2267–2294PubMedCrossRef Shane E, Burr D, Ebeling PR et al (2010) Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 25:2267–2294PubMedCrossRef
7.
go back to reference Shane E, Burr D, Abrahamsen B et al (2013) Atypical subtrochanteric and diaphyseal femoral fractures: second Report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. doi:10.1002/jbmr.1998 Shane E, Burr D, Abrahamsen B et al (2013) Atypical subtrochanteric and diaphyseal femoral fractures: second Report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. doi:10.​1002/​jbmr.​1998
9.
go back to reference Paparodis R, Buehring B, Pelley EM, Binkley N (2013) A case of an unusual subtrochanteric fracture in a patient receiving denosumab. Endocr Pract 19(3):e64-8PubMedCrossRef Paparodis R, Buehring B, Pelley EM, Binkley N (2013) A case of an unusual subtrochanteric fracture in a patient receiving denosumab. Endocr Pract 19(3):e64-8PubMedCrossRef
10.
go back to reference Schilcher J, Michaelsson K, Aspenberg P (2011) Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 364:1728–1737PubMedCrossRef Schilcher J, Michaelsson K, Aspenberg P (2011) Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 364:1728–1737PubMedCrossRef
11.
go back to reference Park-Wyllie LY, Mamdani MM, Juurlink DN et al (2011) Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA 305:783–789PubMedCrossRef Park-Wyllie LY, Mamdani MM, Juurlink DN et al (2011) Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA 305:783–789PubMedCrossRef
12.
go back to reference Black DM, Kelly MP, Genant HK et al (2010) Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med 362:1761–1771PubMedCrossRef Black DM, Kelly MP, Genant HK et al (2010) Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med 362:1761–1771PubMedCrossRef
13.
go back to reference Kim SY, Schneeweiss S, Katz JN et al (2011) Oral bisphosphonates and risk of subtrochanteric or diaphyseal femur fractures in a population-based cohort. J Bone Miner Res 26:993–1001PubMedCrossRefPubMedCentral Kim SY, Schneeweiss S, Katz JN et al (2011) Oral bisphosphonates and risk of subtrochanteric or diaphyseal femur fractures in a population-based cohort. J Bone Miner Res 26:993–1001PubMedCrossRefPubMedCentral
14.
go back to reference Feldstein AC, Black D, Perrin N et al (2012) Incidence and demography of femur fractures with and without atypical features. J Bone Miner Res 27:977–986PubMedCrossRef Feldstein AC, Black D, Perrin N et al (2012) Incidence and demography of femur fractures with and without atypical features. J Bone Miner Res 27:977–986PubMedCrossRef
15.
go back to reference Giusti A, Hamdy NA, Dekkers OM et al (2011) Atypical fractures and bisphosphonate therapy: a cohort study of patients with femoral fracture with radiographic adjudication of fracture site and features. Bone 48:966–971PubMedCrossRef Giusti A, Hamdy NA, Dekkers OM et al (2011) Atypical fractures and bisphosphonate therapy: a cohort study of patients with femoral fracture with radiographic adjudication of fracture site and features. Bone 48:966–971PubMedCrossRef
16.
go back to reference Beaudouin-Bazire C, Dalmas N, Bourgeois J et al (2013) Real frequency of ordinary and atypical sub-trochanteric and diaphyseal fractures in France based on X-rays and medical file analysis. Joint Bone Spine 80(2):201–205PubMedCrossRef Beaudouin-Bazire C, Dalmas N, Bourgeois J et al (2013) Real frequency of ordinary and atypical sub-trochanteric and diaphyseal fractures in France based on X-rays and medical file analysis. Joint Bone Spine 80(2):201–205PubMedCrossRef
17.
go back to reference Spangler L, Ott SM, Scholes D (2011) Utility of automated data in identifying femoral shaft and subtrochanteric (diaphyseal) fractures. Osteoporos Int 22:2523–2527PubMedCrossRef Spangler L, Ott SM, Scholes D (2011) Utility of automated data in identifying femoral shaft and subtrochanteric (diaphyseal) fractures. Osteoporos Int 22:2523–2527PubMedCrossRef
18.
go back to reference Dell RM, Adams AL, Greene DF, Funahashi TT, Silverman SL, Eisemon EO, Zhou H, Burchette RJ, Ott SM (2012) Incidence of atypical nontraumatic diaphyseal fractures of the femur. J Bone Miner Res 27(12):2544–2550PubMedCrossRef Dell RM, Adams AL, Greene DF, Funahashi TT, Silverman SL, Eisemon EO, Zhou H, Burchette RJ, Ott SM (2012) Incidence of atypical nontraumatic diaphyseal fractures of the femur. J Bone Miner Res 27(12):2544–2550PubMedCrossRef
20.
go back to reference Meier RP, Perneger TV, Stern R, Rizzoli R, Peter RE (2012) Increasing occurrence of atypical femoral fractures associated with bisphosphonate use. Arch Intern Med 172(12):930–936PubMedCrossRef Meier RP, Perneger TV, Stern R, Rizzoli R, Peter RE (2012) Increasing occurrence of atypical femoral fractures associated with bisphosphonate use. Arch Intern Med 172(12):930–936PubMedCrossRef
21.
go back to reference Schilcher J, Koeppen V, Ranstam J, Skripitz R, Michaëlsson K, Aspenberg P (2013) Atypical femoral fractures are a separate entity, characterized by highly specific radiographic features. A comparison of 59 cases and 218 controls. Bone 52(1):389–392PubMedCrossRef Schilcher J, Koeppen V, Ranstam J, Skripitz R, Michaëlsson K, Aspenberg P (2013) Atypical femoral fractures are a separate entity, characterized by highly specific radiographic features. A comparison of 59 cases and 218 controls. Bone 52(1):389–392PubMedCrossRef
22.
go back to reference Nieves JW, Bilezikian JP, Lane JM et al (2010) Fragility fractures of the hip and femur: incidence and patient characteristics. Osteoporos Int 21(3):399–408PubMedCrossRef Nieves JW, Bilezikian JP, Lane JM et al (2010) Fragility fractures of the hip and femur: incidence and patient characteristics. Osteoporos Int 21(3):399–408PubMedCrossRef
23.
go back to reference Wang Z, Bhattacharyya T (2011) Trends in incidence of subtrochanteric fragility fractures and bisphosphonate use among the US elderly, 1996–2007. J Bone Miner Res 26:553–560PubMedCrossRefPubMedCentral Wang Z, Bhattacharyya T (2011) Trends in incidence of subtrochanteric fragility fractures and bisphosphonate use among the US elderly, 1996–2007. J Bone Miner Res 26:553–560PubMedCrossRefPubMedCentral
24.
25.
go back to reference Abrahamsen B (2013) Are long-term bisphosphonate users a reality? Dose years for current bisphosphonate users assessed using the Danish national prescription database. Osteoporos Int 24(1):369–372PubMedCrossRef Abrahamsen B (2013) Are long-term bisphosphonate users a reality? Dose years for current bisphosphonate users assessed using the Danish national prescription database. Osteoporos Int 24(1):369–372PubMedCrossRef
26.
go back to reference Cramer JA, Gold DT, Silverman SL, Lewiecki EM (2007) A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 18(8):1023–1031PubMedCrossRef Cramer JA, Gold DT, Silverman SL, Lewiecki EM (2007) A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 18(8):1023–1031PubMedCrossRef
27.
go back to reference Burden AM, Paterson JM, Solomon DH, Mamdani M, Juurlink DN, Cadarette SM (2012) Bisphosphonate prescribing, persistence and cumulative exposure in Ontario Canada. Osteoporos Int 23(3):1075–1082PubMedCrossRefPubMedCentral Burden AM, Paterson JM, Solomon DH, Mamdani M, Juurlink DN, Cadarette SM (2012) Bisphosphonate prescribing, persistence and cumulative exposure in Ontario Canada. Osteoporos Int 23(3):1075–1082PubMedCrossRefPubMedCentral
28.
go back to reference Puhaindran ME, Farooki A, Steensma MR, Hameed M, Healey JH, Boland PJ (2011) Atypical subtrochanteric femoral fractures in patients with skeletal malignant involvement treated with intravenous bisphosphonates. J Bone Joint Surg Am 93:1235–1242PubMedCrossRef Puhaindran ME, Farooki A, Steensma MR, Hameed M, Healey JH, Boland PJ (2011) Atypical subtrochanteric femoral fractures in patients with skeletal malignant involvement treated with intravenous bisphosphonates. J Bone Joint Surg Am 93:1235–1242PubMedCrossRef
29.
go back to reference Abrahamsen B (2011) Older women who use bisphosphonate for longer than 5 years may have increased odds of a subtrochanteric or femoral shaft fracture, but absolute risk is low. Evid Based Med 16:168–169PubMedCrossRef Abrahamsen B (2011) Older women who use bisphosphonate for longer than 5 years may have increased odds of a subtrochanteric or femoral shaft fracture, but absolute risk is low. Evid Based Med 16:168–169PubMedCrossRef
30.
go back to reference Black DM, Bauer DC, Schwartz AV et al (2012) Continuing bisphosphonate treatment for osteoporosis—for whom and for how long? N Engl J Med 366(22):2051–2053PubMedCrossRefPubMedCentral Black DM, Bauer DC, Schwartz AV et al (2012) Continuing bisphosphonate treatment for osteoporosis—for whom and for how long? N Engl J Med 366(22):2051–2053PubMedCrossRefPubMedCentral
31.
32.
go back to reference Curtis JR, Westfall AO, Cheng H, Delzell E, Saag KG (2008) Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday. Osteoporos Int 19(11):1613–1620PubMedCrossRefPubMedCentral Curtis JR, Westfall AO, Cheng H, Delzell E, Saag KG (2008) Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday. Osteoporos Int 19(11):1613–1620PubMedCrossRefPubMedCentral
34.
go back to reference Brown JP, Morin S, Leslie W et al (2014) Bisphosphonates for treatment of osteoporosis. Expected benefits, potential harms, and drug holidays. Can Fam Physician 60:324–333PubMedPubMedCentral Brown JP, Morin S, Leslie W et al (2014) Bisphosphonates for treatment of osteoporosis. Expected benefits, potential harms, and drug holidays. Can Fam Physician 60:324–333PubMedPubMedCentral
35.
go back to reference Sampalis JS, Adachi JD, Rampakakis E et al (2012) Long-term impact of adherence to oral bisphosphonates on osteoporotic fracture incidence. J Bone Miner Res 27(1):202–210PubMedCrossRef Sampalis JS, Adachi JD, Rampakakis E et al (2012) Long-term impact of adherence to oral bisphosphonates on osteoporotic fracture incidence. J Bone Miner Res 27(1):202–210PubMedCrossRef
36.
go back to reference Abrahamsen B (2012) Atypical femur fractures: refining the clinical picture. J Bone Miner Res 27:975–976PubMedCrossRef Abrahamsen B (2012) Atypical femur fractures: refining the clinical picture. J Bone Miner Res 27:975–976PubMedCrossRef
Metadata
Title
Identifying Atypical Femoral Fractures—A Retrospective Review
Authors
Angela G. Juby
Sean Crowther
Marilyn Cree
Publication date
01-11-2014
Publisher
Springer US
Published in
Calcified Tissue International / Issue 5/2014
Print ISSN: 0171-967X
Electronic ISSN: 1432-0827
DOI
https://doi.org/10.1007/s00223-014-9908-x

Other articles of this Issue 5/2014

Calcified Tissue International 5/2014 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.